期刊文献+

去唾液酸糖蛋白受体特异性单链抗体的优化表达及亲和常数的测定 被引量:5

Optimized expression of a single-chain Fv antibody against human asialoglycoprotein receptor and determination of its affinity constant
下载PDF
导出
摘要 目的:表达及纯化抗去唾液酸糖蛋白受体(ASG-PR)的单链抗体的可溶性,并测定其亲和常数。方法:用噬菌体C1克隆感染E.coliHB2151,挑取单个菌落接种于2×TY培养基中,于37℃震荡培养过夜。将培养物作1∶100稀释并转种后,用终浓度为0.25、0.5、1.0mmol/L的IPTG,分别在37℃、25℃和20℃下诱导表达过夜。取其培养上清,用饱和硫酸铵沉淀后,以120g/LSDS-PAGE分析。另外,将饱和硫酸铵沉淀物用30mLPBS重新溶解、透析除盐后,用Ni2+螯合柱进行纯化,再以120g/LSDS-PAGE鉴定纯化scFvC1的纯度。用非竞争酶免疫法测定scFv的亲和常数。结果:用0.5mmol/LIPTG在25℃诱导过夜,表达的scFvC1的量较多,其相对分子质量(Mr)约为28000,以可溶性的形式存在于培养基中。通过Ni2+亲和柱纯化后scFvC1的纯度在95%以上,产量约为0.8mg/L。scFv的亲和常数为(2.31±0.36)×10-7mol/L。结论:以筛选的C1噬菌体感染E.coliHB2151后可表达低亲和力的可溶性scFv,对肝癌的基因治疗具有潜在的应用价值。 AIM: To express and purify a single chain Fv antibody (scFv) C1 against human hepatic asialoglycoprotein receptor (ASGPR) and to determine affinity constant of the purified scFv C1. METHODS: The specific anti-ASGPR phage clone C1 was transfected into E. coil HB2151. The single colony was chosen to be inoculated into 2 × TY medium and shaken (2.50 r/min) overnight at 37℃. After 1 in 100 dilution in 2 × TY medium and induced for secreted expression, scFv C1 was induced at different concentrations (0.25, 0.5 and 1.0 mmol/L IPTG) overnight at 37℃, 25℃ and 20℃, respectively. The supernatant was precipitated with saturated ammonium sulfate and its sediment was analyzed by SDS-PAGE. In addition, the sediment was resuspended in 30 mL PBS and dialyzed against PBS overnight at 4℃. The expressed scFv C1 was purified by Ni^2+ chelating HiTrap HP column and the purity of the purified scFv C1 was identified by SDS-PAGE. Then affinity constant of scFv C1 was determined by noncompetitive enzyme immunoassay. RESULTS. After induced with 0.5 mmol/L IPTG overnight at 25℃(3, the amount of expressed scFv C1 increased greatly and its M, was about 28 000, and it existed in culture supernant in soluble form. The purity of scFv C1 by nickel-agarose column was above 9.5% and its yield was about O. 8 mg/L.The affinity constant of the purified scFv C1 was confirmed to be (2.31 ±0. 36) × 10^-7 mol/L. CONCLUSION: The E. coli HB2151 infected with phage C1 clones may expresssoluble scFv C1 with low affinity, which has potential applications to gene therapy of hepatocellular carcinoma.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2006年第4期504-506,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 湖北省科技攻关计划基金资助(AA301C43)
关键词 去唾液酸糖蛋白受体 单链抗体 表达 亲和常数 asialoglycoprotein receptor single-chain Fv expression affinity constant
  • 相关文献

参考文献9

二级参考文献18

  • 1Zhu ZP, Witte L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor[J]. Invest New Drugs, 1999, 17(3): 195-212. 被引量:1
  • 2Xiong D, Xu Y, Liu H, et al. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody[J]. Cancer Lett, 2002, 177(1): 29-39. 被引量:1
  • 3Zhu Z, Rockwell P, Lu D, et al. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library[J]. Cancer Res, 1998, 58(15): 3209-3214. 被引量:1
  • 4Zhu Z, Lu D, Kotanides H, et al. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody[J]. Cancer Lett, 1999, 136(2): 203-213. 被引量:1
  • 5Stockert RJ. The asialoglycoprotein receptors: relationships between structure, function, and expression. Physiol Rev, 1995, 75(3): 591-593. 被引量:1
  • 6Wu GY, Wu CH. Delivery systems for gene therapy. Biotherapy, 1991, 被引量:1
  • 7(1): 87-95.3.Tomlinson IM, Williams SC, Corbett SJ, et al. V base Sequence Directory. MRC Center for Protein Engineering, Cambridge, 1996, 1: 120-125. 被引量:1
  • 8Trere D, Fiume L, De Giorgi LB, et al. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells.Br J Cancer, 1999, 81(3): 404-408. 被引量:1
  • 9Wu J, Nantz MH, Zem MA. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci, 2002, 被引量:1
  • 10: 717-725.7.Leath CA 3rd, Douglas JT, Curiel DT, et al. Single-chain antibodies: A therapeutic modality for cancer gene therapy (review). Int J Oncol,2004, 24(4): 765-771. 被引量:1

共引文献14

同被引文献38

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部